Oprelvekin Product Approval Information - Licensing Action

Proper name: Oprelvekin
Tradename: Neumega
Manufacturer: Genetics Institute, Inc, Andover, MA, License #1163
Indication for Use: Prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia
Approval Date: 11/25/97
Type of submission: Biologics license application


Approval Letter - (PDF)

Reviews - (PDF)
    Clinical (54 pages)
    Clinical pharmacokinetic (17 pages)
    CMC 1 (4 pages)
    CMC 2 (3 pages)
    Pharmacology (56 pages)
    Statistical (33 pages)


Page Last Updated: 05/06/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English